Peptic Ulcer Drugs Market: Global Industry Trends, Growth Drivers, and Forecast
The Peptic Ulcer Drugs Market is witnessing steady expansion as the global healthcare industry responds to the continued prevalence of gastrointestinal disorders and the growing need for effective ulcer management therapies.
According to Market Research Future, the global market was valued at USD 5.71 billion in 2025 and is projected to reach USD 9.74 billion by 2035, registering a CAGR of 5.48% during the forecast period.
The market includes proton pump inhibitors, H2 antagonists, antacids, and other pharmacological treatments used for gastric, duodenal, and esophageal ulcers. Proton pump inhibitors continue to represent a major portion of the market because of their established clinical use and broad availability.
Increasing awareness of Helicobacter pylori infection, the aging population, NSAID-associated ulcer incidence, and improvements in diagnosis and treatment are supporting market demand. At the same time, innovative potassium-competitive acid blockers are creating new opportunities for pharmaceutical companies.
North America currently represents a leading regional market, while Asia-Pacific is expected to register strong growth during the forecast period. Increasing healthcare access, screening programs, and pharmaceutical development across emerging economies are expected to contribute to future market expansion.